CA
AUPH icon

CoreCap Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

CoreCap Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13K Hold
800
– – ﹤0.01% 1981
2026
Q2 		$13.6K Sell
800
-1,385
-63% -$22.1K ﹤0.01% 1960
2026
Q1 		$32.4K Sell
2,185
-22,584
-91% -$330K ﹤0.01% 1488
2025
Q4 		$395K Buy
24,769
+23,969
+2,996% +$340K 0.01% 573
2025
Q3 		$8.84K Hold
800
– – ﹤0.01% 1993
2025
Q2 		$6.78K Hold
800
– – ﹤0.01% 2027
2025
Q1 		$6.43K Hold
800
– – ﹤0.01% 2004
2024
Q4 		$7.18K Hold
800
– – ﹤0.01% 1889
2024
Q3 		$5.86K Hold
800
– – ﹤0.01% 1935
2024
Q2 		$4.57K Hold
800
– – ﹤0.01% 1187
2024
Q1 		$4.01K Buy
+800
New +$5.43K ﹤0.01% 1965
2022
Q4 		$3.46K Buy
+800
New +$4.64K ﹤0.01% 1836
2022
Q3 		– Sell
-800
Closed -$8K – 646
2022
Q2 		$8K Buy
+800
New +$8.94K ﹤0.01% 1527
2022
Q1 		– Sell
-800
Closed -$18K – 655
2021
Q4 		$18K Buy
+800
New +$19K ﹤0.01% 1354

Other funds holding AUPH

JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
AIM
Acropolis Investment Management St. Louis, Missouri $2.49B AUM 10.8% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors's AUPH Position: Q3 2026 in Review

CoreCap Advisors held its Aurinia Pharmaceuticals (AUPH) position steady in Q3 2026 at 800 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #1981.

CoreCap Advisors first reported a position in AUPH in Q4 2021 and has held it in 14 quarters since. The position peaked at $395K in Q4 2025. 5 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • CoreCap Advisors held 800 shares of Aurinia Pharmaceuticals worth $13K as of Q3 2026.
  • CoreCap Advisors left its Aurinia Pharmaceuticals share count unchanged in Q3 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1981 holding.
  • CoreCap Advisors first reported a position in Aurinia Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
  • CoreCap Advisors's Aurinia Pharmaceuticals position peaked at $395K in Q4 2025.
  • 5 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.